Cabozantinib is a multikinase inhibitor of VEGFR2, RET, and hepatocyte growth factor receptor (c-MET), which was approved for the treatment of MTC after the demonstration of PFS advantages in the group treated with the TKI compared with the placebo group (11.2 months versus 4 months, respectively, p < 0.0001) in a phase III, randomized, double-blind study conducted on 330 patients with MTC and radiologically confirmed disease progression (20). This evidence concerns the gene RET and medullary thyroid gland carcinoma.